

Hong Kong Science and Technology Parks Corp strengthens collaboration with AstraZeneca

04 April 2023 | News

Leading Hong Kong in pioneering life science innovation in Greater Bay Area, and setting an example for the region

Hong Kong Science and Technology Parks Corporation (HKSTP) continues to strengthen the strategic partnership with AstraZeneca, one of the world's leading pharmaceutical companies. The goal of this collaboration is to position Hong Kong and the Greater Bay Area as a trailblazer in life science innovation and serve as a model for the region. This marks a milestone that HKSTP has entered into a multidimensional collaboration, which includes technology and data sharing, with a life science corporation.

Since 2021, AstraZeneca and HKSTP have been collaborating, and this partnership will not only continue but also be upgraded. The extended collaboration involves AstraZeneca and HKSTP supporting and providing services to startup companies under the HKSTP co-incubation programme.

Additionally, the collaboration includes attracting more overseas and China mainland companies to the HKSTP community, with the aim of connecting them with hospitals, key opinion leaders in the Greater Bay Area, and universities in Hong Kong.

The 2022 Policy Address emphasised the city's commitment to fostering innovation and technology. AstraZeneca and HKSTP share the same aspiration to partner with the HKSAR government to improve the healthcare ecosystem in Hong Kong.

AstraZeneca will also provide consultation on setting up international offices in Hong Kong and support connecting overseas investors with HKSTP co-incubation programmes. Besides, roadshow sessions at HKSTP will be held for overseas and China R&D Health Conferences to forge non-traditional partnerships across geographical boundaries, facilitating collaborative action and opening up new opportunities to enhance patient-enabled innovation.

Image caption- Albert Wong, CEO of Hong Kong Science and Technology Parks (left, front row) and Shan Wu, General Manager, AstraZeneca Hong Kong and Macau (right, front row) signed the Co-incubation Programme.